Beyond Air Q3 FY2024 net loss $16.2M; revenues $0.4M; FY2025 guidance reiterated $12-16M

Beyond Air, Inc.

2024-Q3 EPS reported -$1.46 revenue$689,000

Net loss $16.2M ($0.50 per share) vs $12.7M ($0.43) in Q3 FY2023; revenues $0.4M from zero prior year.
FY2025 revenue guidance reiterated at $12M-$16M; LungFit PH filter shipments up >100% QoQ.
PMA supplement for cardiac surgery label expansion accepted for filing and under FDA substantive review.
Cash, marketable securities $31.4M as of Dec 31, 2023; raised $5.5M via ATM to offset burn.
CMO Dr. Myers transitions to consultant effective Feb 16; CCO Duncan Fatkin leaves March 31.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Beyond Air, Inc. reported third quarter of fiscal year 2024 (fiscal quarter ended December 31, 2023) results: revenue $0.4 million, net income ($16.2) million, EPS ($0.50) per share, basic and diluted. Guidance reaffirmed.

Period: third quarter of fiscal year 2024 (fiscal quarter ended December 31, 2023)
Revenue: $0.4 million
Net income: ($16.2) million
EPS: ($0.50) per share, basic and diluted
Guidance: reaffirmed
Result: reported results

Exact text from the filing

and will provide updates as appropriate 2 Financial Results for the Fiscal Quarter Ended December 31, 2023 Revenues for the three months ended December 31, 2023 were $0.4 million compared to zero for the quarter ended December 31, 2022. Cost of revenue of $0.7 million was recognized for the three months ended December 31, 2023, compared to $0.1 million

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Beyond Air, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-007013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.